Skip to main content

Eosinophilic Esophagitis (EoE)

0
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
2 programs
dupilumabN/AMonoclonal Antibody
DupilumabPHASE_3Monoclonal Antibody
Sanofi
SanofiPARIS, France
1 program
dupilumabN/AMonoclonal Antibody1 trial
Active Trials
NCT06693531Recruiting350Est. May 2030
One Biosciences
One BiosciencesFrance - Paris
1 program
Solrikitug Low DosePHASE_21 trial
Active Trials
NCT06598462Active Not RecruitingEst. Aug 2027
Takeda
TakedaTOKYO, Japan
1 program
Budesonide oral suspensionPHASE_31 trial
Active Trials
NCT03245840Terminated133Est. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
TakedaBudesonide oral suspension
One BiosciencesSolrikitug Low Dose
Sanofidupilumab

Clinical Trials (3)

Total enrollment: 483 patients across 3 trials

NCT03245840TakedaBudesonide oral suspension

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

Start: Oct 2017Est. completion: Apr 2022133 patients
Phase 3Terminated
NCT06598462One BiosciencesSolrikitug Low Dose

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

Start: Oct 2024Est. completion: Aug 2027
Phase 2Active Not Recruiting

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Start: Nov 2024Est. completion: May 2030350 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 483 patients
Monoclonal Antibody is the dominant modality (100% of programs)
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.